As the world observes World Tuberculosis Day, it is important to reflect on both the progress achieved and the ongoing challenges posed by this ancient disease. Tuberculosis (TB), a disease that has haunted humanity for millennia, continues to claim over a million lives annually despite being preventable and curable.
Historical Perspective
Tuberculosis has long been intertwined with human history. Notable writers such as John Keats, Franz Kafka, D H Lawrence, and George Orwell all succumbed to the disease. In the 18th and 19th centuries, TB was known as the “White Plague,” devastating European cities where it accounted for up to one in seven deaths. Archaeological evidence shows that TB has affected humans for over 3,000 years, with ancient Egyptian mummies showing signs of spinal deformities linked to the disease. Modern DNA analysis has confirmed TB’s presence in ancient remains, highlighting its longstanding relationship with humanity.
In literature, TB was romanticized as a disease associated with sensitivity and artistic genius, often depicted in tragic narratives. This perception persisted until 1882, when German scientist Robert Koch identified the Mycobacterium tuberculosis bacterium, proving that TB is infectious rather than hereditary. This discovery led to the establishment of global TB control efforts and the annual observance of March 24th as World Tuberculosis Day.
Current Global Situation
Despite over a century of scientific understanding, TB remains one of the deadliest infectious diseases worldwide. According to the World Health Organization, approximately 10.6 million people contracted TB in 2022–23, resulting in about 1.3 million deaths each year. The disease continues to threaten vulnerable populations, especially in low- and middle-income countries.
Prevention and Challenges
The Bacillus Calmette–Guérin (BCG) vaccine, developed over a century ago, remains a vital tool, especially for protecting children from severe forms such as tuberculous meningitis. Administered at birth in many countries, including India under its Universal Immunization Programme, the BCG vaccine offers limited protection against pulmonary TB—the most common and contagious form affecting adults and adolescents. Pulmonary TB spreads through airborne droplets, making it highly transmissible in crowded settings.
India bears the largest share of the global TB burden, accounting for roughly 27–28% of cases. While recent years have seen positive trends—such as a 20–21% decline in incidence between 2015 and 2024, surpassing the global average decline of 10–12%—the scale of the challenge remains formidable. Efforts through the National Tuberculosis Elimination Programme, including expanded screening and rapid diagnostics, have increased treatment coverage.
Persistent Challenges
Despite these efforts, the fight against TB faces numerous hurdles. Overcrowded environments facilitate transmission, while delayed diagnosis hampers containment. Poverty and undernutrition increase individual vulnerability, and the lengthy treatment process—lasting at least six months—poses adherence challenges. Interruptions in therapy can lead to drug-resistant TB, complicating treatment and prolonging recovery.
Ensuring patients complete their full course of treatment is crucial not only for their recovery but also for preventing the emergence of resistant strains. Standard therapy cures about 85–90% of drug-sensitive TB cases when followed correctly, but lapses in treatment undermine these gains.
A Call for Continued Action
As the world marks World Tuberculosis Day, the persistent presence of TB underscores that medical solutions alone are insufficient. Greater awareness, robust public health infrastructure, and sustained global commitment are essential to eliminate this preventable and curable disease. Only through collective action can TB’s long history as a deadly killer be brought to an end.
